PDCD1 and heart failure: Since PD-1/PD-L1 inhibitors associated with cardiotoxicity may progress rapidly and cause hemodynamic instability, clinicians should maintain a high degree of alertness to patients receiving immunotherapy and showing symptoms of heart failure.